Huperzine A (SPN-817)

Small molecule

Also known as BIS-001

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Dravet Syndrome

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Epilepsy
NCT05518578 · Supernus Pharmaceuticals, Inc.
2023-02-07 – 2027-12-31 · Epilepsy, Seizures, Epileptic
What this study did
NCT07141329 · Supernus Pharmaceuticals, Inc.
2025-07-30 – 2027-12-31 · Focal Onset Seizures
What this study did
Phase 1/2 (1)
Epilepsy
NCT03474770 · Supernus Pharmaceuticals, Inc.
2018-04-10 – 2026-12-30 · Focal Impaired Awareness Seizures
What this study did
Phase 1 (2)
Epilepsy
Other / comorbidity
NCT05102552 · Supernus Pharmaceuticals, Inc.
2021-10-19 – 2022-08-15 · Healthy Volunteer
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Dravet Syndrome: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Huperzine A (SPN-817): this drugStage not on recordSmall moleculeAcetylcholinesterasenot yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Donepezil (Aricept)
Approved(overall)
Small moleculeAcetylcholinesterase
Partial signal(overall)
No reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
NCT02926898: Change in monthly convulsive seizure frequency over titration plus maintenance, fenfluramine 0.4 mg/kg/day (n=43) vs placebo (n=44), in Dravet syndrome on stiripentol-inclusive regimens: 54.0% greater reduction with fenfluramine (95% CI 35.6% to 67.2%); ANCOVA p<0.001 (CT.gov posted analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
ZorevunersenPhase 3RNA / oligonucleotideSCN1A mRNAWeak signalNo reviewed efficacy summary in this indication
Cannabidiol (Kanbis)
Phase 2(overall)
Small moleculecannabinoidnot yet gradedNo reviewed efficacy summary in this indication
GB-5001
Phase 1(overall)
Small moleculeAcetylcholinesterase
Weak signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Huperzine A (SPN-817) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1/2EpilepsyActive not recruiting
Est. primary completion 2026-12-30 · NCT03474770 · CT.gov ↗
What to watch
2027 (3)
August 2027 (1)
Phase 2EpilepsyRecruiting
Est. primary completion 2027-08 · NCT06798896 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2EpilepsyRecruiting
Est. primary completion 2027-12-31 · NCT05518578 · CT.gov ↗
What to watch
Phase 2EpilepsyEnrolling by invitation
Est. primary completion 2027-12-31 · NCT07141329 · CT.gov ↗
What to watch

See the full readout calendar ↗